Roivant Sciences Ltd

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Roivant Sciences reports strong Q1 earnings and explores new opportunities

Roivant Sciences demonstrated strong financial performance, with positive results for key programs and a substantial cash position. While facing challenges in patent litigation and DTC campaign optimization, the company has opportunities to leverage payer work, explore new therapeutic potentials, and capitalize on transaction opportunities.

ROIV reports positive trial results and potential in autoimmune diseases

ROIV's earnings call highlights positive trial results, potential in autoimmune diseases, and upcoming Phase III study results. The company acknowledges challenges in proving efficacy in lupus but is optimistic about brepocitinib's potential in various indications.

Roivant Sciences doubles revenue in Q3, VTAMA gains traction

Roivant Sciences delivered strong financial results and progress in its pipeline, particularly with the successful launch of VTAMA and enrollment in key studies.
While facing challenges in market penetration and patient behavior trends, the company's strategic focus on innovation and financial discipline positions it for future success.
By leveraging opportunities in expanding indications, advancing pipeline assets, and strategic collaborations, Roivant is poised for sustained growth and value creation.

Roivant Sciences reports robust Q4 earnings and strategic growth outlook

Roivant Sciences delivered a strong financial performance with notable achievements in clinical programs and a robust cash position, indicating stability and growth potential.
While facing challenges in patient consent for biomarker analysis and legal uncertainties, the company is strategically positioned to leverage opportunities in expanding its pipeline and exploring new markets.
With a focus on balancing operational challenges and pursuing strategic growth initiatives, Roivant Sciences remains well-positioned for future success in the biopharmaceutical industry.

Roivant Sciences excels in Q1 2024 with promising autoimmune therapies

Roivant Sciences demonstrated strong performance and promising results in Q1 2024 across multiple programs
Brepocitinib's unique mechanism positions it as a potential leader in autoimmune therapies, with significant market opportunities
Capital decisions post-Immunovant data and pricing strategy alignment present challenges for Roivant
Opportunities lie in rapid commercial launches, blockbuster potential in orphan indications, and prescription acceleration strategies

Roivant Sciences excels in Q2 with $7B cash post-sale

Roivant Sciences delivered a solid performance in Q2 2024, showcasing financial strength, positive clinical outcomes, and strategic focus on value creation. While facing challenges in margin optimization and market competition, the company is well-positioned to leverage opportunities in unmet medical needs and strategic partnerships for growth.

Roivant Sciences reports strong Q3 performance and outlines growth plans

Roivant Sciences showcased strong performance with key successes and efficient development models. The company faces challenges in certain clinical trials but remains optimistic about growth opportunities. By focusing on strategic growth and efficient execution, Roivant aims to capitalize on its promising pipeline and commercial potential.

Roivant Sciences excels in Q4, eyes blockbuster sales and strategic partnerships

Roivant Sciences is strategically positioned with a focus on maximizing pipeline opportunities, prioritizing data-driven decisions, and capitalizing on the differentiation potential of brepocitinib.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BASEL, Switzerland and LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the strongest efficacy data in NIU observed to date. Roivant also announced that its board of directors has authorized a share repurchase program for up to $1.5 billion of the company's common shares, including the repurchase of all 71.3 million shares held by Sumitomo Pharma at a purchase price of $9.10 per share. The aggregate purchase price for the Sumitomo Pharma transaction is approximately $648.4 million and will reduce Roivant's shares outstanding as of February 9, 2024 by approximately 9%.

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Roivant Sciences Ltd. has seen a slight gain of 10% in its stock over the past 10 months, since my "buy" recommendation last May. The company has a differentiated drug development pipeline targeting multi-billion dollar indications, thanks to its unique "Vant" subsidiaries and some smart dealmaking. Last October, Swiss Pharma giant Roche paid >$7bn to acquire Televant, and acquire U.S. and Japanese rights to late stage autoimmune drug RVT-3101.

Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success

Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript

BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update.

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update

Roivant Sciences operates with an innovative business model through its subsidiaries, specializing in specific therapeutic areas such as immuno-dermatology and autoimmune disorders. Notable achievements include the sale of Telavant to Roche, the successful performance of Vtama cream for psoriasis, and advancements in clinical trials for atopic dermatitis and IMVT-1402 antibody development. Despite the lack of immediate catalysts and ongoing cash burn, the stock trades at a substantial discount relative to its sector, making it a "buy" at current levels.

Roivant Sciences: Why Its 'Vant' Biotech Model Is A Buy

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves' disease meaningfully exceeded 50% response rates.

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion. Telavant holds the rights in the US and Japan to RVT-3101, a promising new therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Prior to the closing of the transaction, Roivant owned 75% of the issued and outstanding shares of common stock and preferred stock of Telavant, on an as-converted basis. An additional payment of $150 million in cash is payable upon the completion of a near-term milestone.

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease

Roivant Sciences stock moved lower on Monday after the biopharmaceutical company announced that its lupus therapeutic oral brepocitinib failed to meet the primary endpoint in a Phase 2 study. The company said it plans to continue progressing the drug in other indications outside of Systemic Lupus Erythematosus (SLE) given its favorable safety and tolerability profile, six other positive Phase 2 studies, and the active arm performance of this study.

Roivant Sciences unable to determine effectiveness of lupus drug in Phase 2 study

Roivant Sciences Ltd. shares ROIV fell 3% premarket on Monday after the company said the experimental treatment brepocitinib failed to meet its main goal in a trial involving patients with moderate to severe lupus.

Roivant Sciences shares drop as lupus treatment misses trial goal

Roivant Sciences said on Monday its experimental drug to treat autoimmune disease systemic lupus erythematosus (SLE) failed to meet the main goal of reducing symptoms in a mid-stage study.

Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2023 Earnings Conference Call November 13, 2023 8:00 AM ET Company Participants Stephanie Lee - Vice President, Special Projects Matt Gline - Chief Executive Officer Mayukh Sukhatme - President and Chief Investment Officer Frank Torti - Managing Director, Vant Chair Conference Call Participants David Risinger - Leerink Partners Brian Cheng - JPMorgan Yaron Werber - TD Cowen Corinne Jenkins - Goldman Sachs Robyn Karnauskas - Truist Securities Louise Chen - Cantor Fitzgerald Douglas Tsao - H.C.

Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript

Roche Holding AG

Roivant Sciences has reported a third-quarter earnings miss but revenue that topped analysts' expectations, sending its shares higher in Monday premarket trading. The company also said it has sufficient cash to fund its programs after it and Pfizer agreed to sell Telavant, manufacturer of an inflammatory bowel disease drug, to Roche for $7.25 billion.

Roivant cash-flush after $7.15B Telavant sale to Roche as it reports mixed 3Q

BASEL, Switzerland and LONDON and NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2023, and provided an update on the business.

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

BASEL, LONDON, and NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 13, 2023, to report its financial results for the second quarter ended September 30, 2023, and provide a business update.

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023

Pfizer

Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. Roivant made $5 billion from the sale, after having only spent $15 million on development. Pfizer originally passed it over to Roivant for free last December.

A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free

Roche Holding AG acquires Telavant Holdings for $7.1B upfront and $150M milestone payment, potentially very interesting deal. Roivant Sciences owns a 75% equity interest in Telavant Holdings. Curiously, Roivant Sciences stock sold off on the news.

Roivant Sciences: Risk-Transforming Deal Met With Crickets

Monday, Roivant Sciences announced an asset sale to Roche. The biotech is slated to earn $5.2 billion upon closing, plus a $110 milestone payment once a late-stage trial commences.

It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy

London-based biotech firm Roivant Sciences (ROIV) agreed to sell its Telavant Holdings unit, which is co-owned by Pfizer (PFE), to Roche Holding for $7.1 billion.

Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion

Roivant Sciences (NASDAQ: ROIV ) stock rose overnight after Roche Holdings (OTCMKTS: RHHBY ) agreed to buy its joint venture with Pfizer (NYSE: PFE ) for $7.1 billion. The joint venture, called Televant, focuses on inflammatory and fibrotic diseases.

Why Is Roivant Sciences (ROIV) Stock Up Today?

Shares of Roivant Sciences Ltd. ROIV, -1.13% and Pfizer Inc. PFE, -1.73% gained ground premarket on Monday after Roche Holding AG RHHBY, +0.51% agreed to buy immunology company Telavant for $7.1 billion.

Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion

The deal is the latest example of a big pharma company turning to the deal table to bolster its pipeline of autoimmune drugs.

Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion

BASEL, Switzerland and LONDON and NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the entry into a definitive agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc. The agreement includes the development, manufacturing and commercialization rights in the US and Japan for RVT-3101, a novel TL1A directed antibody. RVT-3101 is a promising new therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Inflammatory bowel disease is a group of chronic gastrointestinal disorders with almost 8 million people diagnosed worldwide and 80% of all individuals not experiencing lasting remission.1 Given the antibody's novel mode of action targeting both inflammation and fibrosis, it has potential to be applied in multiple other diseases.

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

Roivant Sciences (NASDAQ: ROIV) stock price surged by more than 15% in the pre-market session after the company made a successful drag exit. The shares surged to a high of $11.20, the highest level since Wednesday.

Roivant Sciences stock: Good news for Vivek Ramaswamy

Roivant Sciences Ltd. (ROIV) saw its shares surge in the last session with trading volume being higher than average.

Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?

Roivant Sciences (NASDAQ: ROIV) stock price surged on Tuesday as investors cheered the latest developments with Immunovant (NASDAQ: IMVT). The shares jumped by more than 20% and retested the year-to-date high of $12.90.

News for Roivant Sciences Ltd Stock (ROIV)